HFM
SNDX icon

Hartford Financial Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Hartford Financial Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,500
Closed -$34K – 375
2019
Q1 		$34K Sell
6,500
-800
-11% -$4.56K 0.01% 232
2018
Q4 		$32K Hold
7,300
– – 0.01% 238
2018
Q3 		$59K Buy
7,300
+6,300
+630% +$44.9K 0.02% 217
2018
Q2 		$7K Buy
+1,000
New +$9.81K ﹤0.01% 345

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hartford Financial Management's SNDX Position: Q2 2019 in Review

Hartford Financial Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2019, closing a stake of 6,500 shares — an estimated $34K sold.

Hartford Financial Management first reported a position in SNDX in Q2 2018 and held it in 4 quarters. The position peaked at $59K in Q3 2018. 71 funds tracked by Wall St. Rank hold SNDX as of Q2 2019.

  • Hartford Financial Management reported no remaining Syndax Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Hartford Financial Management sold 6,500 Syndax Pharmaceuticals shares in Q2 2019, an estimated $34K.
  • Hartford Financial Management first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Hartford Financial Management's Syndax Pharmaceuticals position peaked at $59K in Q3 2018.
  • 71 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2019.

Based on Hartford Financial Management's 13F filing for Q2 2019, filed 1 Aug 2019.